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Volume 52, Number 2 Abstracts 519about the value of raising HDL-C. There is therefore also a need to reliably
characterize the relationship between HDL-C and vascular risk, especially at
the high HDL-C levels (N Engl J Med 2007;357:2109-22). Given uncer-
tainties of the relationship between LDL-C and HDL-C levels and the
various manifestations of vascular disease, as well as the uncertainties of the
roll of proatherogenic lipoproteins in various types of vascular disease, the
authors sought to produce reliable estimates of the association of major
lipids and apolipoproteins with respect to risk for ischemic stroke and
coronary heart disease (CHD). A total of 112 prospective studies of cardio-
vascular risk factors involving 1.2 million participants with shared individual
medical records are in the Emerging Risk Factors Collaboration (ERFC).
Sixty-eight studies involving 302,430 participants without any known his-
tory of CHD at initial examination also had complete information on
baseline levels of total cholesterol, HDL-C, and triglyceride, and several
conventional risk factors for vascular disease (diabetes, blood pressure, body
mass index, smoking status, age, and sex). These patients had a total of 2.79
million person-years of follow-up. During follow-up, there were 8857
nonfatal myocardial infarctions, 2534 ischemic strokes, 3928 coronary heart
disease deaths, 513 hemorrhagic strokes, and 2536 unclassified strokes. The
lipid information and the outcome information was used to calculate hazard
ratios adjusted for conventional variables. Rates of CHD per 1000 person-
years in the bottom and top thirds of baseline lipid distributions, respec-
tively, were 2.6 and 2.2 for triglycerides, 6.4 and 2.4 for HDL-C, and 2.3
and 6.7 for non-HDL-C. The adjusted hazard ratio for CHDwas 0.99 (95%
CI 0.94-1.04) for triglycerides, 0.78 (95% CI 0.74-0.82) for HDL-C, and
1.5 (95% CI, 1.39-1.61) for non-HDL-C. Hazard ratios were as strong in
participants who did not fast as those did. A combination of 80 mg/dL
lower non-HDL-C and 15 mg/dL high HDL-C resulted in a hazard ratio
for CHDof 0.35 (95% CI, 0.3-0.42). For the subset with apolipoproteins or
directly measured LDL-C, hazard ratios were 1.5 (95% CI, 1.38-1.62), with
a ratio of non-HDL-C/HDL-C the hazard ratio was 1.49 (95% CI, 1.39-
1.60), with a ratio of apo B/apo A1, the hazard ratio was 1.42 (95% CI,
1.06-1.91), and with a non-HDL-C the hazard ratio was 1.38 (95% CI,
1.09-1.73). With directly measured LDL-C, hazard ratios for ischemic
stroke were 1.02 (95% CI, 0.94-1.11) with triglycerides, 0.93 (95% CI,
0.84-1.02) with HDL-C, and 1.12 (95% CI, 1.04-1.20) with non-HDL-C.
Comment: The data are important but complicated as presented. Never-
theless, the implications of the findings can be simplified as follows: What to
measure in vascular risk assessment depends more on practical considerations
rather than major differences in strength of epidemiologic associations. In
addition, hazard ratios for vascular disease with lipid levels are of similar
magnitude in fasted and non-fasted patients. Hazard ratios are also similar with
directlymeasuredLDL-Candnon-HDL-C. Finally, triglyceride concentrations
are not independently related to coronary heart disease risk. The bottom line is
that lipid assessment for stratifying vascular risk can done by measuring either
total cholesterol andHDL-C levels or apolipoproteins, without the need to fast
and without the need to monitor triglycerides.
National Outcomes after Open Repair of Abdominal Aortic Aneurysms
with Visceral or Renal Bypass
Martin MC, Giles KA, Pomposelli FB, et al. Ann Vasc Surg 2010;24:
106-12.
Conclusion: Mortality of open abdominal aortic aneurysm (AAA)
repair that includes visceral or renal artery bypass is higher than for open
AAA repair without visceral or renal artery bypass and depends on increasing
age and the presence of renal or congestive heart failure.
Summary:There is extensive literature evaluating the outcome of open
infrarenal AAA repairs. However, when AAA repair includes a visceral or
renal artery bypass, data are much more limited (Ann Surg 1996;223:555-
67; Langenbecks Arch Surg 2007;392:725-30). In this study, the authors
sought to evaluate national outcomes of open elective AAA repair with and
without a mesenteric or renal artery bypass and predictors of risk and
perioperative mortality.
The National Inpatient Sample database from 1993 to 2006 was used.
ICD-9 codes for open repair of intact AAA were used to identify open AAA
repairs with and without visceral or renal artery bypass (VRB). VRBs were
defined as aortorenal and/or mesenteric bypass or a mesenteric endarterec-
tomy. Patients with aortic dissections were excluded. Complications and
mortality of patients with standard open repairs of infrarenal AAAs were
compared with those patients who also had visceral or renal artery bypass.
Multivariate logistic regression analysis was then used to analyze predictors
of perioperative mortality.
The study identified 31,166 VRB and 362, 808 infrarenal AAA repairs.
Over the time period, VRB repair volume decreased by 58% and open
infrarenal AAA repair volume decreased by 59%. Mortality was higher in the
VRB patients (5.8 vs 4.4%, P .01). There were more complications in the
VRB patients: acute renal failure, 9.5% vs 6.0% (P  .01), acute mesenteric
ischemia, 2.0% vs 1.2%; and bowel resection, 1.1% vs 0.8% (P  .01).
Mortality was 10 times more likely if the patient required a bowel resection
or developed acute renal failure. Independent preoperative predictors of
mortality were VRB (odds ratio [OR], 1.3; 95% CI, 1.2-1.5), age (OR, 1.4
per decade; 95% CI, 1.4-1.5), chronic renal failure (OR, 5.5; 95% CI,4.9-6.3), congestive heart failure (OR, 7.5; 95% CI, 6.1-9.3), and pulmo-
nary disease (OR, 1.2; 95% CI, 1.1-1.2).
Comment: This study has all the advantages and disadvantages of a
myriad of similar studies that are appearing in the vascular surgical literature.
Such studies are limited in their ability to distinguish primary diagnoses and
procedures and accurately identify comorbid conditions and complications.
The database used here, the National Inpatient Sample, does not actually
analyze all patients. They use sampling weightings to derive total population
estimates. Nevertheless, the conclusion that open AAA repair combined
with visceral or renal artery bypass has higher mortality and complication
rates than standard infrarenal open AAA repair makes sense. This combined
with the recently published ASTRAL trial (N Engl J Med 2009;361:1953-
62) should make surgeons reconsider performance of renal revascularization
as part of AAA repair if the renal revascularization is not integral to the repair.
Randomized Placebo-Controlled Crossover Trial of Tadalafil in
Raynaud’s Phenomenon Secondary to Systemic Sclerosis
Schiopu E, Hsu VM, Impens AJ, et al. J Rheumatol 2009;36:2264-8.
Conclusion: Tadalafil is well tolerated and safe in patients with sys-
temic sclerosis but lacks efficacy in comparison with placebo.
Summary: The endothelial injury of systemic sclerosis is associated
with decreased nitric oxide production (Kahaleh et al, Rheum Diseases Clin
N Am 2008;34:57-71). Type V cyclic GMP phosphodiesterase (PDE-5)
affects the tone of smooth muscle. An intracellular regulator of smooth
muscle tone is cyclic nucleotide monophosphate, cGMP. Nitric oxide syn-
thase produces nitric oxide. Through a complex pathway, nitric oxide
facilitates conversion of GTP into cGMP. PDE-5 breaks down intracellular
cGMP. Therefore, inhibition of PDE-5 results in increased availability of
intracellular cGMP and results in vasodilatation. Tadalafil is a PDE-5 inhib-
itor effective in the use of male erectile dysfunction. However, PDE-5
inhibitors have also been suggested as beneficial in patients with severe
Raynaud’s syndrome (Fries R et al, Circulation 2005;119:2980-5). Tadalafil
is an intriguing PDE-5 inhibitor in that it has a half-life of 17.5 hours and
efficacy up to 36 hours. The pharmacokinetics of tadalafil are not affected by
food or alcohol, age, diabetes, or moderate hepatic insufficiency. It therefore
would seem an ideal drug for facilitating vasodilatation in patients with
Raynaud’s syndrome. This was a randomized, prospective, double-blind,
placebo-controlled, crossover study comparing oral tadalafil with a fixed
daily dose of 20 mg for 4 weeks vs placebo. The study was conducted in
patients with Raynaud’s syndrome secondary to systemic sclerosis. Thirty-
nine completed the study. All patients fulfilled American College of Rheu-
matology classification criteria for systemic sclerosis. All were at least 18 years
of age and had evidence of at least six Raynaud’s attacks during the 2-week
pretreatment period. Patients with unstable angina, congestive heart failure,
or use of nitrites for angina pectoris or any other condition as well as those
with significant central nervous system disease were excluded. Before enroll-
ment, all patients discontinued any other type of vasodilator. Patients were
evaluated for duration and frequency of Raynaud’s attacks and Raynaud
condition scores (RCS). At the end of the evaluation period, there were no
significant statistical differences in RCS scores, frequency of Raynaud’s
attacks, or duration of Raynaud’s attacks between the treatment and placebo
groups.
Comment: The results of the study are disappointing but not conclu-
sive. The participants in this trial had a longer duration of Raynaud’s
syndrome than those in other trials. Severity of Raynaud’s syndrome second-
ary to systemic sclerosis often increases over time. Patients heremay have had
greater endothelial cumulative damage than those in other studies. Other
studies have primarily evaluated the effect of PDE-5 inhibitors on ulcer
healing. Only two patients in this study had active digital ulcers. However,
overall, the current results do not support the use of tadalafil as treatment for
Raynaud’s syndrome secondary to systemic sclerosis at the dosage of 20
mg/d. The study was also burdened by a large placebo effect.
Renal Artery Revascularization Improves Heart Failure Control in
Patients with Atherosclerotic Renal Artery Stenosis
Kane GC, Xu N, Mistrik E, Roubicek T, et al. Nephrol Dial Transplant
2010;25:813-20.
Conclusion: Patients with atherosclerotic renal artery stenosis (RAS)
presenting for percutaneous transluminal renal angioplasty have an increased
risk of death after renal angioplasty. Renal artery revascularization results in
improvement in heart failure control and a reduction in heart failure-related
hospitalizations.
Summary: RAS is associated with abnormalities of left ventricular
function and structure as well as episodes of flash pulmonary edema (acute
left ventricular failure). These are thought to be mediated through labile
systemic hypertension with exacerbation of myocardial ischemia (J Am Soc
Nephrol 2005;16:2746-53; N Engl J Med 2001;344:17-22). Progressive
RAS can be a major determinant of outcome in patients with heart failure
(J Am Coll Cardiol 2006;47:1987-96). Frequently accepted indications for
renal artery revascularization include episodes of flash pulmonary edema,
